Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

Investigational New Drugs, 05/07/2012

The combination of gemcitabine and salirasib appears well–tolerated, with no alteration of salirasib exposure, and exerted clinical and PD activity in pancreatic adenocarcinoma (PDA).

Print Article Summary